Viatris Receivables 2010-2024 | VTRS

Viatris receivables for the quarter ending September 30, 2024 were $3.717B, a 0.56% decline year-over-year.

  • Viatris receivables for 2023 were $3.7B, a 2.99% decline from 2022.
  • Viatris receivables for 2022 were $3.815B, a 10.59% decline from 2021.
  • Viatris receivables for 2021 were $4.266B, a 11.92% decline from 2020.

Viatris Receivables 2010-2024 | VTRS

  • Viatris receivables for 2023 were $3.7B, a 2.99% decline from 2022.
  • Viatris receivables for 2022 were $3.815B, a 10.59% decline from 2021.
  • Viatris receivables for 2021 were $4.266B, a 11.92% decline from 2020.
Related Stocks
Company NameMarket
Cap
Elevance Health (ELV)$88.4B
Cencora (COR)$45.7B
Natera (NTRA)$23.1B
DiDi Global (DIDIY)$22B
ICON (ICLR)$18B
Avantor (AVTR)$14.7B
Revvity (RVTY)$13.9B
BioMerieux (BMXMF)$12.6B
CochLear (CHEOY)$12.1B
Solventum (SOLV)$11.6B
Medpace Holdings (MEDP)$10.9B
Doximity (DOCS)$9.7B
EUROFINS SCIENT (ERFSF)$9.7B
Charles River Laboratories (CRL)$9.5B
HealthEquity (HQY)$8.7B
Sonic Healthcare (SKHHY)$8.2B
Bausch + Lomb (BLCO)$6.3B
Amplifon S.p.A (AMFPF)$5.9B
Organon (OGN)$4.1B
Sotera Health (SHC)$3.7B
BrightSpring Health Services (BTSG)$3B
Surgery Partners (SGRY)$2.6B
Concentras Parent (CON)$2.5B
GeneDx Holdings (WGS)$2.5B
Alignment Healthcare (ALHC)$2.3B
Ardent Health Partners (ARDT)$2.3B
Premier (PINC)$2B
PACS (PACS)$2B
GoodRx Holdings (GDRX)$1.7B
Teladoc Health (TDOC)$1.7B